TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various … Read more
TaiRx, Inc. (6580) - Total Assets
Latest total assets as of June 2025: NT$609.18 Million TWD
Based on the latest financial reports, TaiRx, Inc. (6580) holds total assets worth NT$609.18 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TaiRx, Inc. - Total Assets Trend (2019–2024)
This chart illustrates how TaiRx, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TaiRx, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
TaiRx, Inc.'s total assets of NT$609.18 Million consist of 79.9% current assets and 20.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 16.7% |
| Accounts Receivable | NT$275.00K | 0.0% |
| Inventory | NT$171.00K | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$127.91 Million | 18.7% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how TaiRx, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TaiRx, Inc.'s current assets represent 79.9% of total assets in 2024, an increase from 70.9% in 2019.
- Cash Position: Cash and equivalents constituted 16.7% of total assets in 2024, up from 10.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, a decrease from 26.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 18.7% of total assets.
TaiRx, Inc. Competitors by Total Assets
Key competitors of TaiRx, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TaiRx, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TaiRx, Inc. generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TaiRx, Inc. is currently not profitable relative to its asset base.
TaiRx, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.60 | 24.17 | 18.47 |
| Quick Ratio | 20.58 | 24.17 | 18.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$452.47 Million | NT$ 582.49 Million | NT$ 494.33 Million |
TaiRx, Inc. - Advanced Valuation Insights
This section examines the relationship between TaiRx, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.25 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -17.9% |
| Total Assets | NT$684.78 Million |
| Market Capitalization | $49.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values TaiRx, Inc.'s assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TaiRx, Inc.'s assets decreased by 17.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TaiRx, Inc. (2019–2024)
The table below shows the annual total assets of TaiRx, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$684.78 Million | -17.87% |
| 2023-12-31 | NT$833.75 Million | +56.12% |
| 2022-12-31 | NT$534.04 Million | -24.42% |
| 2021-12-31 | NT$706.62 Million | -15.61% |
| 2020-12-31 | NT$837.30 Million | +71.11% |
| 2019-12-31 | NT$489.34 Million | -- |